Active Ingredients: Norfloxacin
+ free Noroxin pill.
All diagnosis of relapses were supplemented by laboratory tests and were successfully retreated with FD MDT.
The results reveal a total number of 103 patients with HS. Concerning the global distribution of HS.
Asia is most predominant 51 patients whereas the occurence in the other continents is distinctly lower Australia: 21. Afnca: 1, North-Amenca: 12.
Europe: 5 patients The most frequent indication for dapsone treatment was leprosy 80 patients with chronic dermatoses, tuberculosis, other infections or prophylactic use in the remaining cases.
Multiple statistical evidence argues against the possibility of a correlation between applied doses of dapsone and occurence or severity of HS The median of latency time intervall from commencement of therapy to manifestation of the HS was 4 to 7 weeks.
Most patients additionally showed hapatic disfunctions of varying seventy from elevation of laboratory values and hepato spleno megaly to jaundice. After withdrawl of dapsone and therapy with glucocorticosteroids 79 cases recovered, whereas 16 showed fatal outcome.
It could be demonstrated that hepatic coma was he most frequent cause of death.
Mathur, Ci rdhar and B. G i rd liar Central JALMA Institute for leprosy, Agra, India SIow absorption, relatively much slower distribution and longer retention in selective tissues are peculiar features of clofazimine metabolism.
CIinical and experimental studies conducted elsewhere have reported that the plasma l eve Is of the drufi are not correlated to t he dose and length of treatment.
There have, however, been n o reports on plasma l eveIs of the drug in relation to the present dosage of 50 mg daily.
A study is therefore, being made at CJIL, Agra to evaluate plasma clofazimine levels in relation to cumulative intake of the drug mostly as 50 mg daily by leprosy patients. With the cumulat ive drug intake ranging from 1.
The mean plasma drug levels were 0. The plasma drug levels seem to be directly related to cumulative drug intake although the relationship Is not so linear.
The steady state appears to be reached after about 30-60 daily doses of 50 mg as reflected by plasma drug levels.
Our findings on clofazimine pharmacokinetics wil l be discussed in the light of the relevance of optimising drug admtnistration in the current scenario of chemotherepy. No relapses were observed.
PB patients also presented earlier after the first symptoms of disease, the detection of MB diminished slightly during the last 3 years. Conclusion: 1.
Short term combined treatment of both PB and MB with excellent results is realizable.
Some treatment regimens applied in the past give rise to relapses after 10 years and more. Although intensive chemotherapy was given during 17 years, the detection rates show some improvement only during the last 3 years, and PB patients show up at an earlier stage.
H of Egypt. Clinic, Ramsis Sq. Since the recommendation of the W.